Effect of Definition of Preradiotherapy Prostate-Specific Antigen Velocity on Its Association with Prostate Cancer-Specific Mortality and All-Cause Mortality

Urology

Volumn 70, Issue 2, 2007, Pages 288-293

  Nguyen, Paul L ^a,b,c   Chen, Ming Hui ^d   Renshaw, Andrew A ^e   Sussman, Brenda ^b,c   D'Amico, Anthony V ^b,c  

^a HARVARD RADIATION ONCOLOGY PROGRAM   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d UNIVERSITY OF CONNECTICUT   (United States)

^e BAPTIST HOSPITAL OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER RADIOTHERAPY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; CAUSE OF DEATH; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 34548436623     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2007.03.061     Document Type: Article

References (15)

1. Freedland S.J., Humphreys E.B., Mangold L.A., et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294 (2005) 433-439
2. Sengupta S., Myers R.P., Slezak J.M., et al. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol 174 (2005) 2191-2196
3. Rozhansky F., Chen M.H., Cox M.C., et al. Prostate-specific antigen velocity and survival for patients with hormone-refractory metastatic prostate carcinoma. Cancer 106 (2006) 63-67
4. Patel D.A., Presti Jr. J.C., McNeal J.E., et al. Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy. J Clin Oncol 23 (2005) 6157-6162
5. D'Amico A.V., Kantoff P., Loffredo M., et al. Predictors of mortality after prostate-specific antigen failure. Int J Radiat Oncol Biol Phys 65 (2006) 656-660
6. Sengupta S., Blute M.L., Bagniewski S.M., et al. Increasing prostate specific antigen following radical prostatectomy and adjuvant hormonal therapy: doubling time predicts survival. J Urol 175 (2006) 1684-1690
7. D'Amico A.V., Moul J.W., Carroll P.R., et al. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 95 (2003) 1376-1383
8. D'Amico A.V., Moul J.W., Carroll P.R., et al. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol 172 5 Pt 2 (2004) S42-S46
9. Lee A.K., Levy L.B., Cheung R., et al. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy. Int J Radiat Oncol Biol Phys 63 (2005) 456-462
10. D'Amico A.V., Renshaw A.A., Sussman B., et al. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 294 (2005) 440-447
11. D'Amico A.V., Chen M., Roehl K., et al. Pre-operative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351 (2004) 125-135
12. American Society for Therapeutic Radiology and Oncology Consensus Panel: Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37 (1997) 1035-1041
13. Cox D. Regression models and life-tables. J R Stat Soc B34 (1972) 187-220
14. Gray R. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16 (1988) 1141-1154
15. Carter H.B., Pearson J.D., Metter E.J., et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267 (1992) 2215-2220